Safety and efficacy of buprenorphine for analgesia in laboratory mice and rats

Lab Animal

Volumn 41, Issue 11, 2012, Pages 337-343

  Guarnieri, Michael ^a   Brayton, Cory ^a   Detolla, Louis ^b   Forbes Mcbean, Nadine ^a   Sarabia Estrada, Rachel ^a   Zadnik, Patricia ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUPRENORPHINE; NARCOTIC ANALGESIC AGENT;

ANALGESIA; ANIMAL; ANIMAL DISEASE; INSTRUMENTATION; METHODOLOGY; MOUSE; POSTOPERATIVE PAIN; RAT; REVIEW;

ANALGESIA; ANALGESICS, OPIOID; ANIMALS; BUPRENORPHINE; MICE; PAIN, POSTOPERATIVE; RATS;

EID: 84867755115     PISSN: 00937355     EISSN: 15484475     Source Type: Journal    
DOI: 10.1038/laban.152     Document Type: Review

References (86)

1. Cowan, A., Lewis, J.W. Macfarlane, I.R. Agonist and antagonist properties of buprenorphine, a new antinociceptive agent. Br. J. Pharmacol. 60, 537-545 (1977). (Pubitemid 8149539)
2. Cowan, A., Doxey, J.C. Harry, E.J. The animal pharmacology of buprenorphine, an oripavine analgesic agent. Br. J. Pharmacol. 60, 547-54 (1977). (Pubitemid 8149540)
3. Orwin, J.M., Orwin, J. Price, M. A double blind comparison of buprenorphine and morphine in conscious subjects following administration by the intramuscular route. Acta Anaesthesiol. Belg. 27, 171-181 (1976). (Pubitemid 8094487)
4. Campbell, N.D. Lovell, A.M. The history of the development of buprenorphine as an addiction therapeutic. Ann. N Y Acad. Sci. 1248, 124-139 (2012).
5. Farris, H.E. Effects of indomethacin and buprenorphine analgesia on the postoperative recovery of mice. J. Am. Assoc. Lab. Anim. Sci. 47, 8 (2008).
6. Stokes, E.L., Flecknell, P.A. Richardson, C.A. Reported analgesic and anaesthetic administration to rodents undergoing experimental surgical procedures. Lab. Anim. 43, 149-154 (2009).
7. Cowan, A. Buprenorphine: new pharmacological aspects. Int. J. Clin. Pract. Suppl. 113, 3-8 (2003). (Pubitemid 36362949)
8. Roughan, J.V. Flecknell, P.A. Buprenorphine: A reappraisal of its antinociceptive effects and therapeutic use in alleviating post-operative pain in animals. Lab. Anim. 36, 322-343 (2002). (Pubitemid 34785767)
9. Gades, N.M., Danneman, P.J., Wixson, S.K. Tolley, E.A. The magnitude and duration of the analgesic effect of morphine, butorphanol, and buprenorphine in rats and mice. Contemp. Top. Lab. Anim. Sci. 39, 8-13 (2000).
10. Karas, A. Postoperative analgesia in the laboratory mouse, Mus musculus. Lab. Anim. (NY) 31, 1-4 (2002).
11. Richardson, C.A. Flecknell, P.A. Anesthesia and post-operative analgesia following experimental surgery in laboratory rodents: Are we making progress? Altern. Lab. Anim. 33, 119-127 (2005). (Pubitemid 40686383)
12. Martin, W.R., Eades, C.G., Thompson, J.A., Huppler, R.E. Gilbert, P.E. The effects of morphine- and nalorphine- like drugs in the nondependent and morphine-dependent chronic spinal dog. J. Pharmacol. Exp. Ther. 197, 517-532 (1976).
13. Virk, M.S., Arttamangkul, S., Birdsong, W.T. Williams, J.T. Buprenorphine is a weak partial agonist that inhibits opioid receptor desensitization. J. Neurosci. 29, 7341-7348 (2009).
14. Tallarida, R.J., Cowan, A. Raffa, R.B. On deriving the dose-effect relation of an unknown second component: An example using buprenorphine preclinical data. Drug Alcohol Depend. 109, 126-129 (2010).
15. Raffa, R.B. Ding, Z. Examination of the preclinical antinociceptive efficacy of buprenorphine and its designation as full- or partial-agonist. Acute Pain 9, 145-152 (2007). (Pubitemid 47499155)
16. Yassen, A., Olofsen, E., Kan, J., Dahan, A. Danhof, M. Pharmacokinetic-pharmacodynamic modeling of the effectiveness and safety of buprenorphine and fentanyl in rats. Pharm. Res. 25, 183-193 (2008).
17. Meyer, M.R. Maurer, H.H. Absorption, distribution, metabolism and excretion pharmacogenomics of drugs of abuse. Pharmacogenomics 12, 215-233 (2011).
18. Gopal, S., Tzeng, T.B. Cowan, A. Characterization of the pharmacokinetics of buprenorphine and norbuprenorphine in rats after intravenous bolus administration of buprenorphine. Eur. J. Pharm. Sci. 15, 287-293 (2002). (Pubitemid 34229143)
19. Pontani, R.B., Vadlamani, N.L. Misra, A.L. Disposition in the rat of buprenorphine administered parenterally and as a subcutaneous implant. Xenobiotica 15, 287-297 (1985). (Pubitemid 15074564)
20. Yu, S. et al. Pharmacokinetics of buprenorphine after intravenous administration in the mouse. J. Am. Assoc. Lab. Anim. Sci. 45, 12-16 (2006). (Pubitemid 43828863)
21. Brown, S.M., Holtzman, M., Kim, T. Kharasch, E.D. Buprenorphine metabolites, buprenorphine-3-glucuronide and norbuprenorphine-3-glucuronide, are biologically active. Anesthesiology 115, 1251-1260 (2011).
22. Heel, R.C., Brogden, R.N., Speight, T.M. Avery, G.S. Buprenorphine: A review of its pharmacological properties and therapeutic efficacy. Drugs 17, 81-110 (1979). (Pubitemid 11144150)
23. Ponsoda, X. et al. The effects of buprenorphine on the metabolism of human hepatocytes. Toxicol. in Vitro. 5, 219-224 (1991).
24. Berson, A. et al. Mechanisms for experimental buprenorphine hepatotoxicity: major role of mitochondrial dysfunction versus metabolic activation. J. Hepatol. 34, 261-269 (2001). (Pubitemid 32176448)
25. Kugawa, F., Arae, K., Ueno, A. Aoki, M. Buprenorphine hydrochloride induces apoptosis in NG108-15 nerve cells. Eur. J. Pharmacol. 347, 105-112 (1998). (Pubitemid 28238093)
26. Ferland, C., Veilleux-Lemieux, D. Vachon, P. Effects of buprenorphine on intracerebral collagenase-induced hematoma in Sprague-Dawley rats. J. Am. Assoc. Lab. Anim. Sci. 46, 13-16 (2007). (Pubitemid 47068011)
27. Yulug, B., Cam, E., Yildiz, A. Kilic, E. Buprenorphine does not aggravate ischemic neuronal injury in experimental focal cerebral ischemia. J. Neuropsychiatry Clin. Neurosci. 19, 331-334 (2007). (Pubitemid 47293908)
28. Kalliokoski, O. et al. The effect of voluntarily ingested buprenorphine on rats subjected to surgically induced global cerebral ischaemia. In Vivo 24, 641-646 (2010).
29. Nakamura, S., Kakinohana, M., Sugahara, K., Kinjo, S. Miyata, Y. Intrathecal morphine, but not buprenorphine or pentazocine, can induce spastic paraparesis after a noninjurious interval of spinal cord ischemia in the rat. Anesth. Analg. 99, 1528-1531 (2004). (Pubitemid 39407309)
30. Wala, E.P. Holtman, J.R. Jr. Buprenorphine-induced hyperalgesia in the rat. Eur. J. Pharmacol. 651, 89-95 (2011).
31. Malek, A. Mattison, D.R. Drugs and medicines in pregnancy: the placental disposition of opioids. Curr. Pharm. Biotechnol. 12, 797-803 (2011).
32. Farid, W.O., Dunlop, S.A., Tait, R.J. Hulse, G.K. The effects of maternally administered methadone, buprenorphine and naltrexone on offspring: review of human and animal data. Curr. Neuropharmacol. 6, 125-150 (2008). (Pubitemid 352024797)
33. Krueger, K.L. Fujiwara, Y. The use of buprenorphine as an analgesic after rodent embryo transfer. Lab Anim. (NY) 37, 87-90 (2008). (Pubitemid 351169679)
34. Goulding, D.R. et al. The effects of perioperative analgesia on litter size in Crl:CD1(ICR) mice undergoing embryo transfer. J. Am. Assoc. Lab. Anim. Sci. 49, 423-426 (2010).
35. Hutchings, D.E., Zmitrovich, A.C., Hamowy, A.S. Liu, P.Y. Prenatal administration of buprenorphine using the osmotic minipump: A preliminary study of maternal and offspring toxicity and growth in the rat. Neurotoxicol. Teratol. 17, 419-423 (1995).
36. Robinson, S.E. Wallace, M.J. Effect of perinatal buprenorphine exposure on development in the rat. J. Pharmacol. Exp. Ther. 298, 797-804 (2001). (Pubitemid 32673433)
37. Robinson, S.E. Effects of perinatal buprenorphine and methadone exposures on striatal cholinergic ontogeny. Neurotoxicol. Teratol. 24, 137-142 (2002). (Pubitemid 34273995)
38. Chiang, Y.C., Hung, T.W., Lee, C.W., Yan, J.Y. Ho, I.K. Enhancement of tolerance development to morphine in rats prenatally exposed to morphine, methadone, and buprenorphine. J. Biomed. Sci. 17, 46 (2010).
39. Banerjee, D. Sarkar, N.K. Haematological changes in buprenorphine-treated mice. Folia Biol. (Krakow) 45, 157-162 (1997). (Pubitemid 28193510)
40. Volker, D., Bate, M., Gentle, R. Garg, M. Oral buprenorphine is anti-inflammatory and modulates the pathogenesis of streptococcal cell wall polymer-induced arthritis in the Lew/SSN rat. Lab. Anim. 34, 423-429 (2000).
41. Hall, T.J., Jagher, B., Schaeublin, M. Wiesenberg, I. The analgesic drug buprenorphine inhibits osteoclastic bone resorption in vitro, but is proinflammatory in rat adjuvant arthritis. Inflamm. Res. 45, 299-302 (1996). (Pubitemid 26197551)
42. Van Loveren, H., Gianotten, N., Hendriksen, C.F., Schuurman, H.J. Van der Laan, J.W. Assessment of immunotoxicity of buprenorphine. Lab. Anim. 28, 355-363 (1994). (Pubitemid 24311832)
43. Hugunin, K.M., Fry, C., Shuster, K. Nemzek, J.A. Effects of tramadol and buprenorphine on select immunologic factors in a cecal ligation and puncture model. Shock 34, 250-260 (2010).
44. Martucci, C., Panerai, A.E. Sacerdote, P. Chronic fentanyl or buprenorphine infusion in the mouse: similar analgesic profile but different effects on immune responses. Pain 110, 385-392 (2004). (Pubitemid 38953304)
45. Swenson, J., Olgun, S., Radjavi, A., Kaur, T. Reilly, C.M. Clinical efficacy of buprenorphine to minimize distress in MRL/lpr mice. Eur. J. Pharmacol. 567, 67-76 (2007). (Pubitemid 46795488)
46. Lindsay, D.S. et al. Buprenorphine does not affect acute murine toxoplasmosis and is recommended as an analgesic in Toxoplasma gondii studies in mice. J. Parasitol. 91, 1488-1490 (2005). (Pubitemid 43235244)
47. D'Elia, M., Patenaude, J., Hamelin, C., Garrel, D.R. Bernier, J. No detrimental effect from chronic exposure to buprenorphine on corticosteroid-binding globulin and corticosensitive immune parameters. Clin. Immunol. 109, 179-187 (2003). (Pubitemid 37338624)
48. Hanson, C.E., Ruble, G.R., Essiet, I. Hartman, A.B. Effects of buprenorphine on immunogenicity and protective efficacy in the guinea pig keratoconjunctivitis model (Sereny test). Comp. Med. 51, 224-229 (2001). (Pubitemid 32661985)
49. Gueye, P.N. et al. Lack of effect of single high doses of buprenorphine on arterial blood gases in the rat. Toxicol. Sci. 62, 148-154 (2001). (Pubitemid 32611370)
50. Chevillard, L., Mégarbane, B., Risède, P. Baud, F.J. Characteristics and comparative severity of respiratory response to toxic doses of fentanyl, methadone, morphine, and buprenorphine in rats. Toxicol. Lett. 191, 327-340 (2009).
51. Dahan, A. et al. Comparison of the respiratory effects of intravenous buprenorphine and fentanyl in humans and rats. Br. J. Anaesth. 94, 825-834 (2005). (Pubitemid 40754001)
52. Ohtani, M., Kotaki, H., Nishitateno, K., Sawada, Y. Iga, T. Kinetics of respiratory depression in rats induced by buprenorphine and its metabolite, norbuprenorphine. J. Pharmacol. Exp. Ther. 281, 428-433 (1997). (Pubitemid 27203097)
53. Yassen, A., Olofsen, E., Kan, J., Dahan, A. Danhof, M. Animal-to-human extrapolation of the pharmacokinetics and pharmacodynamic properties of buprenorphine. Clin. Pharmacokinet. 46, 433-447 (2007). (Pubitemid 46686468)
54. Adamson, T.W. et al. Assessment of carprofen and buprenorphine on recovery of mice after surgical removal of the mammary fat pad. J. Am. Assoc. Lab. Anim. Sci. 49, 610-616 (2010).
55. Watson, P.J., McQuay, H.J., Bullingham, R.E., Allen, M.C. Moore, R.A. Single-dose comparison of buprenorphine 0.3 and 0.6 mg i.v. given after operation: clinical effects and plasma concentration. Br. J. Anaesth. 54, 37-43 (1982). (Pubitemid 12212361)
56. Chawarski, M.C., Schottenfeld, R.S., O'Connor, P.G. Pakes, J. Plasma concentrations of buprenorphine 24 to 72 hours after dosing. Drug Alcohol Depend. 55, 157-163 (1999). (Pubitemid 29222014)
57. Yassen, A., Olofsen, E., Dahan, A. Danhof, M. Pharmacokinetic- Pharmacodynamic modeling of the antinociceptive effect of buprenorphine and fentanyl in rats: Role of receptor equilibration kinetics. J. Pharmacol. Exp. Ther. 313, 1136-1149 (2005). (Pubitemid 40727017)
58. Liu, K.S. et al. Novel depots of buprenorphine have a long-acting effect for the management of physical dependence to morphine. J. Pharm. Pharmacol. 58, 337-344 (2006).
59. Christoph, T. et al. Broad analgesic profile of buprenorphine in rodent models of acute and chronic pain. Eur. J. Pharmacol. 507, 87-98 (2005). (Pubitemid 40126844)
60. Canta, A. et al. Continuous buprenorphine delivery effect in streptozotocine-induced painful diabetic neuropathy in rats. J. Pain 10, 961-968 (2009).
61. Tubbs, J.T. et al. Effects of buprenorphine, meloxicam, and flunixin meglumine as postoperative analgesia in mice. J. Am. Assoc. Lab. Anim. Sci. 50, 185-191 (2011).
62. Jablonski, P., Howden, B.O. Baxter, K. Influence of buprenorphine analgesia on post-operative recovery in two strains of rats. Lab. Anim. 35, 213-222 (2001). (Pubitemid 32592308)
63. Bourque, S.L., Adams, M.A., Nakatsu, K. Winterborn, A. Comparison of buprenorphine and meloxicam for postsurgical analgesia in rats: effects on body weight, locomotor activity, and hemodynamic parameters. J. Am. Assoc. Lab. Anim. Sci. 49, 617-622 (2010).
64. Brennan, M.P., Sinusas, A.J., Horvath, T.L., Collins, J.G. Harding, M.J. Correlation between body weight changes and postoperative pain in rats treated with meloxicam or buprenorphine. Lab Anim. (NY) 38, 87-93 (2009).
65. Gillingham, M.B., Clarke, M.D., Dahly, E.M., Krugner-Higby, L.A. Ney, D.M. A comparison of two opioid analgesics for relief of visceral pain induced by intestinal resection in rats. Contemp. Top. Lab. Anim. Sci. 40, 21-26 (2001). (Pubitemid 33673081)
66. Matsumiya, L.C. et al. Using the Mouse Grimace Scale to reevaluate the efficacy of postoperative analgesia in laboratory mice. J. Am. Assoc. Lab. Anim. Sci. 51, 42-49 (2012).
67. McKeon, G.P. et al. Analgesic effects of tramadol, tramadol-gabapentin, and buprenorphine in an incisional model of pain in rats (Rattus norvegicus). J. Am. Assoc. Lab. Anim. Sci. 50, 192-197 (2011).
68. Chappell, M.G., Koeller, C.A. Hall, S.I. Differences in postsurgical recovery of CF1 mice after intraperitoneal implantation of radiotelemetry devices through a midline or flank surgical approach. J. Am. Assoc. Lab. Anim. Sci. 50, 227-237 (2011).
69. Karas, A.Z. Barriers to assessment and treatment of pain in laboratory animals. Lab. Anim. (NY) 35, 38-45 (2006). (Pubitemid 44257870)
70. Cooper, D.M., Hoffman, W., Wheat, N. Lee, H.Y. Duration of effects on clinical parameters and referred hyperalgesia in rats after abdominal surgery and multiple doses of analgesia. Comp. Med. 55, 344-353 (2005).
71. Stewart, L.S. Martin, W.J. Influence of postoperative analgesics on the development of neuropathic pain in rats. Comp. Med. 53, 29-36 (2003). (Pubitemid 36323511)
72. Biaha, M.D. Leon, L.R. Effects of indomethacin and buprenorphine analgesia on the postoperative recovery of mice. J. Am. Assoc. Lab. Anim. Sci. 47, 8-19 (2008).
73. Bomzon, A. Are repeated doses of buprenorphine detrimental to postoperative recovery after laparotomy in rats? Comp. Med. 56, 114-118 (2006).
74. Guarnieri, M., Carson, B.S., Khan, A., Penno, M. Jallo, G.I. Flexible versus rigid catheters for chronic administration of exogenous agents into central nervous system tissues. J. Neurosci. Methods 144, 147-152 (2005). (Pubitemid 40720139)
75. Curtin, L.I. et al. Evaluation of buprenorphine in a post-operative pain model in rats. Comp. Med. 59, 60-71 (2009).
76. Jessen, L., Christensen, S. Bjerrum, O.J. The antinociceptive efficacy of buprenorphine administered through the drinking water of rats. Lab. Anim. 41, 185-96 (2007). (Pubitemid 46733406)
77. Leach, M.C., Forrester, A.R. Flecknell, P.A. Influence of preferred foodstuffs on the antinociceptive effects of orally administered buprenorphine in laboratory rats. Lab. Anim. 44, 54-58 (2010).
78. van Loo, P.L. et al. Analgesics in mice used in cancer research: reduction of discomfort? Lab. Anim. 31, 318-325 (1997). (Pubitemid 27462535)
79. Kalliokoski, O., Jacobsen, K.R., Hau, J. Abelson, K.S. Serum concentrations of buprenorphine after oral and parenteral administration in male mice. Vet. J. 187, 251-254 (2011).
80. Goldkuhl, R., Jacobsen, K.R., Kalliokoski, O., Hau, J. Abelson, K.S. Plasma concentrations of corticosterone and buprenorphine in rats subjected to jugular vein catheterization. Lab. Anim. 44, 337-343 (2010).
81. Park, I. et al. Buprederm, a new transdermal delivery system of buprenorphine: pharmacokinetic, efficacy and skin irritancy studies. Pharm. Res. 25, 1052-1062 (2008).
82. Yun, M.H., Jeong, S.W., Pai, C.M. Kim, S.O. Pharmacokinetic- pharmacodynamic modeling of the analgesic effect of Buprederm in mice. Health 2, 824-831 (2010).
83. Pontani, R.B. Misra, A.L. A long-acting buprenorphine delivery system. Pharmacol. Biochem. Behav. 18, 471-474 (1983). (Pubitemid 13146909)
84. Forbes, N. et al. Morbidity and mortality rates associated with serial bleeding from the superficial temporal vein in mice. Lab Anim. (NY) 39, 236-240 (2010).
85. Foley, P.L., Liang, H. Crichlow, A.R. Evaluation of a sustained-release formulation of buprenorphine for analgesia in rats. J. Am. Assoc. Lab. Anim. Sci. 50, 198-204 (2011).
86. Hayes, K.E., Raucci, J.A. Jr., Gades, N.M. Toth, L.A. An evaluation of analgesic regimens for abdominal surgery in mice. Contemp. Top. Lab. Anim. Sci. 39, 18-23 (2000).